Anticancer Therapies – News and Features

Immunovaccine Inc. announced that it will focus the Phase I/II clinical development plan for DPX-Survivac on ovarian cancer.

Bio Elpida has obtained cell therapies production certification from the French regulatory bodies.

Preclinical Oncology Services Limited (PRECOS) has signed a significant service agreement with a leading global pharmaceutical company Janssen Pharmaceutica N.V. The contract will see PRECOS provide clinical tumour material, tumour model development, target validation and drug efficacy work to support Janssen’s oncology drug discovery, development and biomarker programmes.

PRECOS to provide clinical expertise to support Janssen’s oncology drug discovery, development and biomarker programmes.

An intriguing study published in Expert Review of Anticancer Therapy has revealed that the signaling protein JAK3 represents a viable target in the treatment of a broad range of B-lineage cancers, including acute lymphoblastic leukemia (ALL).

Foundation Medicine, Inc., a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis to routine clinical care, have announced the appointment of Maureen T. Cronin, Ph.D., to the newly created position of senior vice president, research and product development.

Radient Pharmaceuticals Corporation (RPC) have announced the launch of a new version of its Onko-Sure® product website, located at www.onko-sure.com.

Researchers have discovered mutations in a particular gene that affects the treatment prognosis for some patients with acute myeloid leukemia (AML), an aggressive blood cancer that kills 9,000 Americans annually.

Company has expanded the capability of its iuvo™ Microconduit Array platform to assess three dimensional cell movement through extracellular matrix.

Partnership is aimed for the development and commercialization of anti-cancer agent CP-4126 in Asia and rest of the World.